Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Development of Sarcopenia in Patients With Bladder Cancer: A Systematic Review

Research output: Contribution to journalReviewResearchpeer-review

  1. Perioperative Alcohol and Smoking Cessation Intervention: Impact on Other Lifestyles

    Research output: Contribution to journalReviewResearchpeer-review

  2. Status of Metastatic Bladder Cancer Treatment Illustrated by a Case

    Research output: Contribution to journalReviewResearchpeer-review

  3. Surgical Management of Muscle Invasive Bladder Cancer: A Review of Current Recommendations

    Research output: Contribution to journalReviewResearchpeer-review

  1. Is the health literacy of informal caregivers associated with the psychological outcomes of breast cancer survivors?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Relative sit-to-stand power: aging trajectories, functionally relevant cut-off points, and normative data in a large European cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risk of Depression After Radical Prostatectomy-A Nationwide Registry-based Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Sarcopenia is known to influence cancer-related complications and overall survival. However, the effect of cancer treatment on the development or progression of sarcopenia is relatively unknown. The primary aim of this systematic review was to determine the prevalence and development of sarcopenia among people with bladder cancer.

DATA SOURCES: A systematic search was performed in PubMed, Web of Science, and EMBASE. Studies with ≥2 assessments of sarcopenia were eligible for inclusion. Five retrospective cohorts were included with a total of 438 participants. The baseline prevalence of sarcopenia across studies varied from 25% to 69% and post-treatment prevalence from 50% to 81%. The average loss of muscle mass was 2.2% to 10% during a time course of 3 to 12 months.

CONCLUSION: The prevalence of sarcopenia markedly increased during cancer treatment in patients with bladder cancer. Further research into the effect of different treatment regimens on the development of sarcopenia, and how these changes might affect functional capacity and survival is needed.

IMPLICATIONS FOR NURSING PRACTICE: The development of sarcopenia is important to understand because of its negative affect on quality of life, complications, and mortality. Further, understanding how sarcopenia develops during treatment could potentially strengthen nurses' future care plans for patients with bladder cancer.

Original languageEnglish
Article number151108
JournalSeminars in Oncology Nursing
Volume37
Issue number1
Pages (from-to)151108
ISSN0749-2081
DOIs
Publication statusPublished - Feb 2021

    Research areas

  • Bladder cancer, Prevalence, Sarcopenia, Systematic review

ID: 61758987